Beloved Australian actor, Magda Szubanski, has revealed she's been diagnosed with a "very rare, very aggressive, very serious" blood cancer called mantle cell lymphoma. In a post on social media on ...

Lymphoma comprises more than 70 non-Hodgkin subtypes; precise classification determines prognosis and drives distinct strategies for aggressive versus indolent disease biology. Management of indolent ...

Stage 3 lymphoma is a type of cancer that starts in a type of white blood cell called lymphocytes and has spread to lymph nodes on both sides of the diaphragm. It may also be in other organs near ...

Named after the 19th-century scientist who first described abnormal masses in the lymph nodes, Hodgkin lymphoma is a cancer of the lymphatic system. Around 10% of lymphoma diagnoses are categorized as ...

Angioimmunoblastic T-cell lymphoma frequently presents with systemic and immune-mediated features that overlap with autoimmune/infectious syndromes, necessitating tissue diagnosis and comprehensive ...

The rare and aggressive DLBCL subtype has a traditionally poor prognosis ...

For 30% to 40% of lymphoma patients who receive CAR T therapy, the treatment is a godsend. Typically given to lymphoma patients for whom other treatments have proven ineffective, CAR T therapy ...

Primary mediastinal B-cell lymphoma (PMBCL) is a rare and aggressive type of non-Hodgkin’s lymphoma that originates in the white blood cells behind the breastbone. Although the cause of PMBCL is ...

Positron emission tomography (PET) is a type of imaging scan that doctors might use when diagnosing and treating non-Hodgkin’s lymphoma (NHL). It can be useful for identifying and staging the cancer.

What Is Marginal Zone Lymphoma? Marginal zone lymphoma (MZL) isn’t one disease, but a group of rare, slow-growing blood cancers. They’re known as non-Hodgkin lymphomas because they start in your ...

It develops from the abnormal multiplication of T cells, or T-lymphocytes, a type of white blood cell essential for immune system function. The specific treatment course and prognosis for T-cell ...